93RD GENERAL ASSEMBLY
State of Illinois
2003 and 2004
HB4964


 
Introduced 02/05/04, by Arthur L. Turner
 
SYNOPSIS AS INTRODUCED:
 		













305 ILCS 5/5-5.12
  from Ch. 23, par. 5-5.12








    Amends the Illinois Public Aid Code.  Provides that the Department shall not impose requirements for prior approval based on a preferred drug list for any short-acting beta agonists used as rescue therapy in the treatment of life-threatening conditions due to acute bronchospasm in patients with reversible obstructive airway disease that results from asthma, chronic obstructive pulmonary disease or emphysema.
















LRB093 20996 RXD 47001 b

















 


 


A BILL FOR









 











HB4964

LRB093 20996 RXD 47001 b






1
    AN ACT in relation to public aid. 

 
2
    Be it enacted by the People of the State of Illinois, 
3
represented in the General Assembly: 


 
4
    Section 5. The Illinois Public Aid Code is amended by 
5
changing Sections
5-5.12 and 9A-11.5 as follows:


 



6
    (305 ILCS 5/5-5.12)  (from Ch. 23, par. 5-5.12)


7
    Sec. 5-5.12. Pharmacy payments. 

8
    (a) Every request submitted by a pharmacy for reimbursement 
9
under this
Article for prescription drugs provided to a 
10
recipient of aid under this
Article shall include the name of 
11
the prescriber or an acceptable
identification number as 
12
established by the Department.

13
    (b) Pharmacies providing prescription drugs under
this 
14
Article shall be reimbursed at a rate which shall include
a 
15
professional dispensing fee as determined by the Illinois

16
Department, plus the current acquisition cost of the 
17
prescription
drug dispensed. The Illinois Department shall 
18
update its
information on the acquisition costs of all 
19
prescription drugs
no less frequently than every 30 days. 
20
However, the Illinois
Department may set the rate of 
21
reimbursement for the acquisition
cost, by rule, at a 
22
percentage of the current average wholesale
acquisition cost.

23
    (c) Reimbursement under this Article for prescription 
24
drugs shall be
limited to reimbursement for 4 brand-name 
25
prescription drugs per patient per
month.  This subsection 
26
applies only if (i) the brand-name drug was not
prescribed for 
27
an acute or urgent condition, (ii) the brand-name drug was not

28
prescribed for Alzheimer's disease, arthritis, diabetes, 
29
HIV/AIDS, a mental
health condition, or respiratory disease, 
30
and (iii) a therapeutically
equivalent generic medication has 
31
been approved by the federal Food and Drug
Administration.

32
    (d) The Department shall not impose requirements for prior 
 


 






HB4964
- 2 -
LRB093 20996 RXD 47001 b




1
approval
based on a preferred drug list for anti-retroviral, 
2
anti-hemophilic factor
concentrates,
or
any atypical 
3
antipsychotics, conventional antipsychotics,
or 
4
anticonvulsants used for the treatment of serious mental

5
illnesses
until 30 days after it has conducted a study of the 
6
impact of such
requirements on patient care and submitted a 
7
report to the Speaker of the
House of Representatives and the 
8
President of the Senate.

9
    (e) The Department shall not impose requirements for prior 
10
approval based on a preferred drug list for any short-acting 
11
beta agonists used as rescue therapy in the treatment of 
12
life-threatening conditions due to acute bronchospasm in 
13
patients with reversible obstructive airway disease that 
14
results from asthma, chronic obstructive pulmonary disease or 
15
emphysema.

16
(Source: P.A. 92-597, eff. 6-28-02; 92-825, eff. 8-21-02; 
17
93-106, eff.
7-8-03.)



 
18
    Section 99. Effective date.   This Act takes effect upon 
19
becoming law.